Tempus Lands Keck Medicine of USC Partnership to Deploy AI Across Patient Care

Overview

• Tempus and the Keck School of Medicine of USC announced a multi‑pillar collaboration that spans clinical testing, trial matching, care‑gap pathways, and research across a network handling over 1.5 million patient visits a year.
• Tempus will embed its molecular diagnostics into Keck Medicine workflows and use its TIME Trial Program to flag patients for targeted therapies, which could help clinicians place eligible patients on the right drugs faster.
• The deal fits Tempus’s two‑sided model in which diagnostics generate revenue and feed a high‑margin data platform, including tools like the Lens analytics suite and AI‑driven trial matching for drug makers.
• Investor coverage highlights a recent move to positive adjusted EBITDA and strong growth in Tempus’s data segment, with attention now turning to the upcoming first‑quarter earnings report.
• Analysts and recent reports continue to flag regulatory oversight, data privacy, and sustained profitability as key risks even as the company accelerates platform adoption.